Company intelligence / Profile preview

Revelar Biotherapeutics

Bethesda, Maryland, United Statesinvestors.twistbioscience.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead antibody RBT-0813 for COVID-19 has demonstrated neutralization of all known SARS-CoV-2 variants of concern in preclinical studies. The company plans to enter clinical studies in 2022.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: AntibodiesBispecific antibodiesVHH single-domain antibodies
Industry: Biotech

Drug pipeline

1 asset

RBT-0813

Preclinical

Partnerships

Twist Bioscience

Beyond the preview

Go deeper on Revelar Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revelar Biotherapeutics.

Explore the full profile